Anika Therapeutics (STU:AKP) Cyclically Adjusted FCF per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AKP Anika Therapeutics Inc STU:AKP
66 GF Score
Price €18.00
GF Value €16.78
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Cyclically Adjusted FCF per Share?

Anika Therapeutics STU:AKP -1.10% 66 Cyclically Adjusted FCF per Share is € as of Jun. 2026. GuruFocus rates STU:AKP with a GF Score™ of 66/100 and a GF Value™ of €16.78 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Anika Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.136. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Anika Therapeutics's average Cyclically Adjusted FCF Growth Rate was -8.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -16.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -10.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Anika Therapeutics was 88.20% per year. The lowest was -18.30% per year. And the median was 19.60% per year.

As of today (2026-09-20), Anika Therapeutics's current stock price is €18.00. Anika Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was . Anika Therapeutics's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Anika Therapeutics was 86.13. The lowest was 7.51. And the median was 21.07.


Anika Therapeutics  (STU:AKP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Anika Therapeutics was 86.13. The lowest was 7.51. And the median was 21.07.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Anika Therapeutics Cyclically Adjusted FCF per Share Related Terms


Anika Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Cyclically Adjusted FCF per Share Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anika Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:AKP vs EBS, ELTP, AKBA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:AKP
66GF Score
Anika Therapeutics Inc STU:AKP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anika Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.136/333.9520*333.9520
=-0.136

Current CPI (Jun. 2026) = 333.9520.

Anika Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.507 241.428 0.701
201612 0.286 241.432 0.396
201703 0.860 243.801 1.178
201706 0.216 244.955 0.294
201709 0.469 246.819 0.635
201712 0.248 246.524 0.336
201803 0.391 249.554 0.523
201806 0.222 251.989 0.294
201809 0.591 252.439 0.782
201812 0.627 251.233 0.833
201903 0.457 254.202 0.600
201906 0.281 256.143 0.366
201909 0.609 256.759 0.792
201912 0.793 256.974 1.031
202003 0.020 258.115 0.026
202006 0.216 257.797 0.280
202009 0.324 260.280 0.416
202012 0.114 260.474 0.146
202103 -0.164 264.877 -0.207
202106 0.112 271.696 0.138
202109 0.044 274.310 0.054
202112 0.203 278.802 0.243
202203 -0.197 287.504 -0.229
202206 0.064 296.311 0.072
202209 0.062 296.808 0.070
202212 -0.136 296.797 -0.153
202303 -0.318 301.836 -0.352
202306 -0.605 305.109 -0.662
202309 0.360 307.789 0.391
202312 0.107 306.746 0.116
202403 -0.121 312.332 -0.129
202406 -0.281 314.175 -0.299
202409 0.242 315.301 0.256
202412 0.013 315.605 0.014
202503 -0.196 319.799 -0.205
202506 -0.088 322.561 -0.091
202509 0.304 324.800 0.313
202512 0.234 324.054 0.241
202603 -0.397 330.213 -0.401
202606 -0.136 333.952 -0.136

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of € mean?
Anika Therapeutics (STU:AKP) has a Cyclically Adjusted FCF per Share of € as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Cyclically Adjusted FCF per Share too high?
Anika Therapeutics' current Cyclically Adjusted FCF per Share is €. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Cyclically Adjusted FCF per Share compare to EBS and ELTP?
Anika Therapeutics' Cyclically Adjusted FCF per Share of € can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Cyclically Adjusted FCF per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Fairly Valued. The stock's GF Value™ is €16.78, compared to a current price of €18.00 — trading 7.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Cyclically Adjusted FCF per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued. The current stock price of €18.00 is trading 7.3% above its estimated GF Value™ of €16.78. GuruFocus considers Anika Therapeutics to be Fairly Valued.

Key valuation signals for STU:AKP:

  • Cyclically Adjusted FCF per Share:
  • GF Value™: €16.78 vs. price of €18.00 (7.3% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score

Get the complete analysis for STU:AKP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.00
Price
€16.78
GF Value